12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MDX-1097: Phase I started

Immune System (formerly PacMab Ltd.) began an open-label, single ascending-dose, Australian Phase I trial to evaluate 0.3, 1.0, 3.0, 10 or 30 mg/kg of intravenous MDX-1097...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >